These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33844614)

  • 1. Design, synthesis and biological evaluation of dipeptides as novel non-covalent 20S proteasome inhibitors.
    Yang YJ; Wang K; Yang Y; Lai FF; Chen XG; Xiao ZY
    J Asian Nat Prod Res; 2021 May; 23(5):436-451. PubMed ID: 33844614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel non-covalent inhibitors selective to the β5-subunit of the human 20S proteasome.
    Xu K; Wang K; Yang Y; Yan DA; Huang L; Chen CH; Xiao Z
    Eur J Med Chem; 2015 Jun; 98():61-8. PubMed ID: 26005024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Terminal functionalized thiourea-containing dipeptides as multidrug-resistance reversers that target 20S proteasome and cell proliferation.
    Qin JM; Huang RZ; Yao GY; Liao ZX; Pan YM; Wang HS
    Eur J Med Chem; 2017 Jan; 126():259-269. PubMed ID: 27889629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors.
    Scotti A; Trapella C; Ferretti V; Gallerani E; Gavioli R; Marastoni M
    J Enzyme Inhib Med Chem; 2016; 31(3):456-63. PubMed ID: 25942361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome.
    Desvergne A; Genin E; Maréchal X; Gallastegui N; Dufau L; Richy N; Groll M; Vidal J; Reboud-Ravaux M
    J Med Chem; 2013 Apr; 56(8):3367-78. PubMed ID: 23540790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors.
    Yang Y; Wang K; Wu B; Yang Y; Lai F; Chen X; Xiao Z
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127508. PubMed ID: 32853683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Basis for the Species-Selective Binding of N,C-Capped Dipeptides to the Mycobacterium tuberculosis Proteasome.
    Hsu HC; Singh PK; Fan H; Wang R; Sukenick G; Nathan C; Lin G; Li H
    Biochemistry; 2017 Jan; 56(1):324-333. PubMed ID: 27976853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
    Ge Y; Li A; Wu J; Feng H; Wang L; Liu H; Xu Y; Xu Q; Zhao L; Li Y
    Eur J Med Chem; 2017 Mar; 128():180-191. PubMed ID: 28182990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
    Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J
    Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of peptidomimetic boronates as proteasome inhibitors.
    Micale N; Ettari R; Lavecchia A; Di Giovanni C; Scarbaci K; Troiano V; Grasso S; Novellino E; Schirmeister T; Zappalà M
    Eur J Med Chem; 2013 Jun; 64():23-34. PubMed ID: 23639651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome.
    Sun Q; Zhou T; Xi D; Li X; Lü Z; Xu F; Wang C; Niu Y; Xu P
    Eur J Med Chem; 2020 Apr; 192():112160. PubMed ID: 32146375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and activity of tyropeptin A derivatives as potent and selective inhibitors of mammalian 20S proteasome.
    Momose I; Umezawa Y; Hirosawa S; Iijima M; Iinuma H; Ikeda D
    Biosci Biotechnol Biochem; 2005 Sep; 69(9):1733-42. PubMed ID: 16195592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome.
    Blackburn C; Barrett C; Blank JL; Bruzzese FJ; Bump N; Dick LR; Fleming P; Garcia K; Hales P; Hu Z; Jones M; Liu JX; Sappal DS; Sintchak MD; Tsu C; Gigstad KM
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6581-6. PubMed ID: 20875739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
    Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome.
    Momose I; Umezawa Y; Hirosawa S; Iinuma H; Ikeda D
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1867-71. PubMed ID: 15780623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studies.
    Lei M; Feng H; Bai E; Zhou H; Wang J; Shi J; Wang X; Hu S; Liu Z; Zhu Y
    Bioorg Med Chem; 2018 Aug; 26(14):3975-3981. PubMed ID: 29934218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TMC-86A, B and TMC-96, new proteasome inhibitors from Streptomyces sp. TC 1084 and Saccharothrix sp. TC 1094. I. Taxonomy, fermentation, isolation, and biological activities.
    Koguchi Y; Kohno J; Suzuki S; Nishio M; Takahashi K; Ohnuki T; Komatsubara S
    J Antibiot (Tokyo); 1999 Dec; 52(12):1069-76. PubMed ID: 10695669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors.
    Zhuang R; Gao L; Lv X; Xi J; Sheng L; Zhao Y; He R; Hu X; Shao Y; Pan X; Liu S; Huang W; Zhou Y; Li J; Zhang J
    Eur J Med Chem; 2017 Jan; 126():1056-1070. PubMed ID: 28027531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
    Niroula D; Hallada LP; Le Chapelain C; Ganegamage SK; Dotson D; Rogelj S; Groll M; Tello-Aburto R
    Eur J Med Chem; 2018 Sep; 157():962-977. PubMed ID: 30165344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
    Zhao Y; Xu L; Zhang J; Zhang M; Lu J; He R; Xi J; Zhuang R; Li J; Zhou Y
    Bioorg Med Chem; 2021 Jan; 29():115867. PubMed ID: 33223460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.